180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the closing of its registered direct offering to a single health care-focused U.S. institutional investor. The offering consisted of 6,132,076 shares of the company’s common stock (including common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock at a purchase price per share (and accompanying warrant) of $1.06. The warrants are initially exercisable beginning six months following the date of issuance, at an exercise price of $1.06 per share, and expire five years from the initial exercise date. 180 Life Sciences intends to use the net proceeds for research and development expenses and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
To view the full press release, visit https://ibn.fm/FaNOj
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company. The company is driving groundbreaking studies into clinical programs, which are seeking to develop treatments for major unmet clinical needs. The company’s primary platform is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.